News
SNAP-CAR

THE PROMISE
OF CELL THERAPY 

Chimeric antigen receptor (CAR) therapy is a new treatment for cancer in which immune cells, either from the patient or from a donor, are genetically engineered to recognize cancer cells to target and destroy them. Currently approved CAR T therapies are revolutionizing the treatment of many blood cancers including B cell leukemias and lymphomas by targeting specific proteins found on these cancers, and there is hope in treating additional cancers including solid tumors by having them recognize new targets.

OUR APPROACH:
SNAP-CAR

Coeptis is developing a novel approach to immune-based cell therapy called SNAP-CAR, where the CAR is connected to tumor cells via a SNAP molecule. Instead of directly binding to tumor cell, the CAR cells are co-administered with one or more antibody adaptors that bind to the tumor cells via a covalent bond. This type of bond is the highest affinity bond possible, thus this binding is expected to translate to highly potent therapeutic activity. The antibody adaptors can be increased (to heighten potency) or decreased (to reduce toxicity) as needed.

PROMISING PRECLINICAL DATA

 

 

related publications

Pre-clinical studies in mice have demonstrated by targeting tumors via antibody adaptor molecules, the SNAP-CAR therapy provides a highly programmable therapeutic platform that may present several potential advantages over standard CAR T treatments. A number of different tumor targets have been successfully tested, with more testing ongoing.

 

 

Society for Immunotherapy of Cancer (SITC) 2023 Poster

Nature Communication (May 2023)

 

SNAP-CAR
In action

Animations herein are provided as visual aids to help articulate hypothesized proof-of-concept in a general manner and do not depict precise scientific mechanisms-of-action.

IMMUNOTHERAPY CHALLENGES

Reducing potential toxicity: The therapeutic activity of SNAP-CAR cells can be controlled by the antibody dose, which we envision would allow clinicians to potentially mitigate toxicity from over-activity. We also envision that the immune response against cancer may also be boosted in patients with additional doses of the tagged tumor-specific antibody. 

THE GOAL

Lowering the chance for cancer relapse: Relapse from CAR T cell therapy which often results from the loss or down-regulation of the targeted protein on the cancer, can potentially be avoided by combining SNAP-CAR cells with antibodies targeting multiple antigens at once. 

A NOVEL APPROACH

Targeting new cancers: SNAP-CAR cells are a platform technology that is being developed to be co-administered with tagged, tumor-specific antibodies to potentially target many different tumor types, including hematological malignancies and solid tumors.

Contact Us

Learn More